Bolt Biotherapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 87

Employees

  • Stock Symbol
  • BOLT

Stock Symbol

  • Share Price
  • $6.10
  • (As of Friday Closing)

Bolt Biotherapeutics General Information

Description

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

Contact Information

Website
www.boltbio.com
Formerly Known As
Bolt Therapeutics, Bolt Therapeutics, Inc.
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 900 Chesapeake Drive
  • Redwood City, CA 94063
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 900 Chesapeake Drive
  • Redwood City, CA 94063
  • United States
+1 (650)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bolt Biotherapeutics Stock Performance

As of 13-Jun-2025, Bolt Biotherapeutics’s stock price is $6.10. Its current market cap is $11.7M with 1.92M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.10 $6.23 $5.20 - $15.60 $11.7M 1.92M 19.7K -$33.40

Bolt Biotherapeutics Financials Summary

As of 31-Mar-2025, Bolt Biotherapeutics has a trailing 12-month revenue of $3.64M.

In Thousands,
USD
TTM 31-Mar-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV (6,774) (15,141) (56,345) (98,930)
Revenue 3,638 7,690 7,876 5,729
EBITDA (66,327) (66,573) (74,296) (88,621)
Net Income (63,347) (63,118) (69,197) (88,098)
Total Assets 85,862 99,632 159,784 227,807
Total Debt 24,709 25,209 20,219 22,611
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Bolt Biotherapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Bolt Biotherapeutics‘s full profile, request access.

Request a free trial

Bolt Biotherapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Bolt Biotherapeutics‘s full profile, request access.

Request a free trial

Bolt Biotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that lev
Drug Discovery
Redwood City, CA
87 As of 2025

Lexington, MA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bolt Biotherapeutics Competitors (41)

One of Bolt Biotherapeutics’s 41 competitors is Agenus, a Formerly VC-backed company based in Lexington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Agenus Formerly VC-backed Lexington, MA
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Nkarta Therapeutics Formerly VC-backed South San Francisco, CA
Lyell Immunopharma Formerly VC-backed South San Francisco, CA
Sorrento Therapeutics Formerly VC-backed San Diego, CA
You’re viewing 5 of 41 competitors. Get the full list »

Bolt Biotherapeutics Patents

Bolt Biotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023216956-A1 Antibody-conjugated 8-sulfonyl-benzazepine compounds and their uses Pending 09-Feb-2022
AU-2023216955-A1 Macromolecule-supported 8-sulfonyl-benzazepine compounds and their uses Pending 09-Feb-2022
EP-4475892-A1 Macromolecule-supported 8-sulfonyl-benzazepine compounds and their uses Pending 09-Feb-2022
EP-4475893-A1 Antibody-conjugated 8-sulfonyl-benzazepine compounds and their uses Pending 09-Feb-2022
US-20250145575-A1 Macromolecule-supported 8-sulfonyl-benzazepine compounds and their uses Pending 09-Feb-2022 C07D223/16
To view Bolt Biotherapeutics’s complete patent history, request access »

Bolt Biotherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bolt Biotherapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Bolt Biotherapeutics‘s full profile, request access.

Request a free trial

Bolt Biotherapeutics ESG

Risk Overview

Risk Rating

Updated December, 06, 2022

31.6 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,638

Rank

Percentile

Pharmaceuticals

Industry

of 1,008

Rank

Percentile

Pharmaceuticals

Subindustry

of 473

Rank

Percentile

To view Bolt Biotherapeutics’s complete esg history, request access »

Bolt Biotherapeutics FAQs

  • When was Bolt Biotherapeutics founded?

    Bolt Biotherapeutics was founded in 2015.

  • Where is Bolt Biotherapeutics headquartered?

    Bolt Biotherapeutics is headquartered in Redwood City, CA.

  • What is the size of Bolt Biotherapeutics?

    Bolt Biotherapeutics has 87 total employees.

  • What industry is Bolt Biotherapeutics in?

    Bolt Biotherapeutics’s primary industry is Drug Discovery.

  • Is Bolt Biotherapeutics a private or public company?

    Bolt Biotherapeutics is a Public company.

  • What is Bolt Biotherapeutics’s stock symbol?

    The ticker symbol for Bolt Biotherapeutics is BOLT.

  • What is the current stock price of Bolt Biotherapeutics?

    As of 13-Jun-2025 the stock price of Bolt Biotherapeutics is $6.10.

  • What is the current market cap of Bolt Biotherapeutics?

    The current market capitalization of Bolt Biotherapeutics is $11.7M.

  • What is Bolt Biotherapeutics’s current revenue?

    The trailing twelve month revenue for Bolt Biotherapeutics is $3.64M.

  • Who are Bolt Biotherapeutics’s competitors?

    Agenus, CytomX Therapeutics, Nkarta Therapeutics, Lyell Immunopharma, and Sorrento Therapeutics are some of the 41 competitors of Bolt Biotherapeutics.

  • What is Bolt Biotherapeutics’s annual earnings per share (EPS)?

    Bolt Biotherapeutics’s EPS for 12 months was -$33.40.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »